Publication:
Statin intensity regimens in Thai type 2 diabetic patients who achieved LDL-C targets

dc.contributor.authorLee B.
dc.contributor.authorDumrongkitchaiporn K.
dc.contributor.authorSriussadaporn S.
dc.contributor.authorThongtang N.
dc.date.accessioned2021-04-05T03:22:18Z
dc.date.available2021-04-05T03:22:18Z
dc.date.issued2017
dc.date.issuedBE2560
dc.description.abstractBackground: Type 2 diabetes mellitus (T2D) increases the risk of developing atherosclerotic cardiovascular disease (ASCVD). Statins reduce ASCVD events and are recommended in patients with T2D. Low-, moderate, and high-intensity regimens are predicted to achieve LDL-C reduction by about <30%, 30% to <50%, and ≥50%, respectively. Objective: To investigate the proportions of different statin intensity regimens used in patients with T2D that achieved LDL-C targets. Material and Method: This retrospective cross-sectional study was conducted in 269 T2D adults with LDL-C <100 mg/dL that were stratified into three groups by statin intensity according to 2013 ACC/AHA guideline. Factors significantly associated with higher-intensity statin use were determined by multivariate analysis. Results: Subjects were mostly elderly with long-standing T2D and hypertension (HT). Prevalence of ASCVD was 12.3%. Only 8.9% received high-intensity statins, while 40.9% and 50.2% received low- and moderate-intensity statins, respectively. Overall, attainment of LDL-C <70 mg/dL was 52.8%. Average LDL-C reduction was 54.6% (49.6%, 54.4%, and 59.7% in the low-, moderate-, and high-intensity groups, respectively). Rates of ASCVD, HT, and smoking were higher in the highintensity group. Factors significantly correlated with higher-intensity statin therapy included diabetic nephropathy (DN), HT, high-density lipoprotein cholesterol (HDL-C), and non-HDL-C levels (OR: 2.633, 2.381, 1.027, and 1.037, respectively). Conclusion: Low- and moderate-intensity statin users accounted for about 90% of Thai T2D patients who achieved LDL-C <100 mg/dL. LDL-C reduction in these two groups was greater than anticipated. HT and DN were associated with the use of higher-intensity statins to achieve LDL-C targets. © 2017, Medical Association of Thailand. All rights reserved.
dc.format.mimetypeapplication/pdf
dc.identifier.citationJournal of the Medical Association of Thailand. Vol 100, No.5 (2017), p.603-611
dc.identifier.issn1252208
dc.identifier.other2-s2.0-85020839307
dc.identifier.urihttps://hdl.handle.net/20.500.14740/4177
dc.rights.holderScopus
dc.subject.otherApolipoprotein B
dc.subject.otherAtorvastatin
dc.subject.otherEzetimibe plus simvastatin
dc.subject.otherHemoglobin A1c
dc.subject.otherHigh density lipoprotein cholesterol
dc.subject.otherHydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subject.otherLow density lipoprotein
dc.subject.otherRosuvastatin
dc.subject.otherTriacylglycerol
dc.subject.otherAdd on therapy
dc.subject.otherAdult
dc.subject.otherArticle
dc.subject.otherBiochemical analysis
dc.subject.otherColorimetry
dc.subject.otherCross-sectional study
dc.subject.otherDiabetic nephropathy
dc.subject.otherDiabetic patient
dc.subject.otherDrug megadose
dc.subject.otherFemale
dc.subject.otherGlycemic control
dc.subject.otherHuman
dc.subject.otherHyperlipidemia
dc.subject.otherHypertension
dc.subject.otherLow drug dose
dc.subject.otherMajor clinical study
dc.subject.otherMale
dc.subject.otherMicroangiopathy
dc.subject.otherMiddle aged
dc.subject.otherNon insulin dependent diabetes mellitus
dc.subject.otherPrevalence
dc.subject.otherRetrospective study
dc.subject.otherRisk factor
dc.subject.otherSmoking
dc.subject.otherTurbidimetry
dc.titleStatin intensity regimens in Thai type 2 diabetic patients who achieved LDL-C targets
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85020839307&partnerID=40&md5=07660c26ed57a11e6180b991997d3af7

Files